A presurgery combination therapy may improve outcomes for women with HER2 positive breast cancer

Treatment Options for HER2+ Breast Cancer: A Comprehensive GuideПодробнее

Treatment Updated for HER2 Positive Breast Cancer: Changing ParadigmsПодробнее

Study comparing margetuximab combinations to trastuzumab combinations in HER2-positive breast cancerПодробнее

Considerations for Pre-operative Therapy to Optimize Care of Women with HER2+ Breast CancerПодробнее

Leveraging Targeted Therapies to Improve Outcomes Across the Continuum of HER2+ Breast CancerПодробнее

Optimizing HER2-Positive Breast Cancer Therapy: Balancing Efficacy and ToxicityПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Reshma MahtaniПодробнее

HER2+ Breast Cancer: Neratinib’s Role as Adjuvant TherapyПодробнее

Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancerПодробнее

Adjuvant Approaches to Treating HER2+ Breast CancerПодробнее

Adjuvant Therapy for Early-Stage HER2-Positive Breast CancerПодробнее

Novel Therapeutics for Breast Cancer: HER2+ and Triple Negative Disease; New Pathways, TargetsПодробнее

Raising the Bar in HER2-Positive Breast CancerПодробнее

Dr. DeMichele on the I-SPY2 Trial for HER2+ Breast CancerПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Mahtani & Dr. SchwartzbergПодробнее

Education Sessions: "The ideal partner to HER2 directed therapies"Подробнее

Sequencing HER2-targeted therapies in breast cancerПодробнее

Neoadjuvant Therapy for HER2-positive Breast Cancer - Dr. Scott ChristensenПодробнее

Optimizing treatment in patients with early-stage HER2-positive breast cancerПодробнее